1. CDC. 1998 Guidelines for treatment of sexually transmitted diseases. MMWR l998;47(No. RR-I).

2. CDC. Hepatitis В virus: a comprehensive strategy for elirninatiitg trans­mission in the United States through universal childhood vaccination— recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR l99l;40(No. RR-13).

3. CDC. Prevention of hepatitis A through aci.ve or passive immuniza­tion: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMJVR 1999;48(No. RR-12).

4. Hatcher RA, Trussell TJ, Stewart FH, et at., eds. Contraceptive technology. 17th ed. New York: Ardent Media, 1998.

5. Drew WL, Blair M, Miner RC, Conant M. Evaluation of the virus permeability of a new condom for women. Sex Transm Dis 1990; 17:110-2.

6. Richardson BA. Nonoxynol-9 as a vaginal mircrobicide for prevention of sexually transmitted infections. JAMA 2002:287:1171-2.

7. Gates W, Stone KM. Family planning, sexually transmitted diseases, and contraceptive choice: a literature update—part 1. Farn Plann Perspectives 1992:24:74-84.

8. CDC. Revised guidelines for HIV counseling, testing, ana referral and revised recommendations for HIV screening of pregnant women. MMWR200l:50(No. RR-19): 13-26.

9. Kamb ML, Fishbein M, Douglas JM, et al. Н1У prevention counsel­ing reduces high risk behaviors and sexually transmitted diseases'. results from a multicenter, randomized controlled trial (Project RESPECT). JAMA 1998:280:1161-7.

10. U.S. Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore, MD: Williams & Wilkins, 1996.

11. American Academy of Pediatrics and American College of Obstetri­cians and Gynecologists. Guidelines for perinatal care. 4th ed. Wash­ington. DC: American Academy of Pediatrics and American College of Obstetricians and Gynecologists, 1997.

12. American College of Obstetricians and Gynecologists. Antimic robial therapy for obstetric patients. Washington, DC: American College of Obstetricians and Gynecologists, March 1998. (Educational bulletin, no. 245.)

13. American College of Obstetricians and Gvnecologists. Committee opin- ion: primary and preventive care. Washington. DC: American College of Obstetricians find Gyneci/iogist\, December 1999. (Penodic assessments, no. 229.)

14. CDC. Recommendations for the prevention and management of Chlamydiatrachomatis infections. 1993. MMWR. 1993;42(No. RR-12).

15. Zanetti AR, Tanzi E, Ne\\ell ML. Mother-to- in/am transmission .hepatitis С virus. J Hepatol 1999:3! (Suppl):96-l 00.

16. Burns DN, Minkoff H. Hepatitis C: screening in pregnancy Obsiel Gynecol 1999:94:1044.

17. American College of Obstetricians and Gynecologists. Viral hepatitis in pregnancy. Washington, DC: American College of Obstetricians and Gynecologists, July 1998. (Educational bulletin, no. 248.)

18. American Academy of Pediatrics and American College of Obstetri­cians and Gynecologists. Human immunodeficiency virus screening' joint statement of the AAP and AGOG. Pediatrics 1999:104:128.

19. Institute of Medicine. Reducing the odds: preventing perinatal trans­mission of HIV in the United States. Washington, DC: National Academy Press, 1999.

20. CDC. Revised US Public Health Service recommendations for human immunodeficiency virus screening of pregnant women. MMWR2001;50(No. RR-I9):59-86.

21. CDC. USPHS/IDSA Prevention of Opportunistic Infections Work­ing Group. 2001 USPHS/JDSA guidelines for the prevention of opportunistic infections in persons infected wth human immunodefi­ciency virus. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, November 28, 2001. Available al http://www.hivatis.org.

22. CDC. Testing for antibodies to human immunodeficiency virus type 2 in the United States. MMWR (in press).

23. Department of Health and Human Services, H"nry J. Kaiser Founda­tion Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. US Department of Health and Human Services, February 4, 2002. Available at hitp./Avvr'w.hivatis.org.

24. Carpenter CJ. Cooper DA, Fi^cbi ЫА, et u\. An'tire'lroviral therapy т adults updated recommendations of the International AIDS Society- " USA Panel JAMA 2000,283 381-90

25. CDC CDC National Prevention Plan Federal Register 2002 (in press)

26. CDC Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus principles of therapy and revised recommendations MMWR 1998 47 (No RR-20)

27. CDC HIV Prevention case management guidance Atlanta GA US Department of Health and Human Services, Public Health Service, September 1997

28. Fowler MG, Simonds RJ, Roongpisuthipong A Update on perinatal HIV transmission Pediatr Clin North Am 2000,47 241-60

29. CDC Recommendations for the ше of antiretroviral drugs in preg­nant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States Atlanta, GA US Department of Health and Human Services, February' 4 2002 Available at http //wwwhivatis org

30. CDC Guidelines for the use of'antiretroviral agents in pediatnc HIV infection Atlanta, GA US Department of Health and Human Services, August 8, 2001 Available at http ffwww hivatis org

31. Wald A New therapies and prevention strategies for genital herpes Clin Infect Dis 1999.28(Suppl) S4-S13

32. Bodsworth NJ, Crooks RJ, Borelli S, et al Valaciclovir versus acyclovir in patient-initiated treatment of genital herpes a randomized, double-blind clinical trial Gemtounn Med 1997 73 110-6

33. Patel R, Bodsworth NJ, Wooley P, et al Valaciclovir for the suppres­sion of recurrent genital HSV infection a placebo controlled study of once-daily therapy Gemtounn Med 1997,73 105-9

34. Spruance S, Trying S, Degregono В, Miller С, Beutner К, the Valaciclovir HSV Study Group A large-scale, placebo-controlled, dose-ranging trial ofperoral valacyclovirfor episodic treatment of recurrent herpes genitalis Arch Int Med 1996,156 1729-35

35. Fife КН. Barbarash RA, Rudolph Т, Degregono В, Roth RE Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection results of an international, multicenter, double-blind randomized clinical trial Sex Transm Dis 1997,24 481-6

36. Reitano M, Tyring S, bang W, et al Valaciclovirfor the suppression of recurrent genital herpes simplex virus infection a large-scale dose range-finding study J Infect Dis 1998 178 603-10

37. Chosidow 0, Drouault Y, Lecontae- Veynac F, et al Famciclo\ir vs aciclovir in immunocompetent patients with recurrent genital herpes infections a parallel-groups, randomized, double-blind clinical trial Br J Dermatol 2001 144 818-24

38. Diaz-Mitoma F. Sibbald RG, Shafran SD, Boon R, Saltzman RL Oral famciclovir for the suppression of recurrent genital herpes a randomized controlled trial JAMA 1998,280887-92

39. Loveless M, Harris W, Sacks S Treatment of first episode genital herpes with famciclovir In Programs and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 1995

40. Mertz GJ, Loveless МО, Levin MJ et al Oral famciclovir for suppres­sion of recurrent genital herpes simplex virus infection in women a multicenter, double-blind, placebo-controlled trial Arch Intern Med 1997.157 343-9

41. Sacks SL. Aoki FY, Diaz-Mitoma F. Sellers J Shafran SD Patient-initiated, twice-daily oral famciclovir for early recurrent genital her­pes a randomized, double-blind multicenter trial JAMA 1996 276 44-9

42. Henry RE, WegmannJA HartleJE, Christopher GW Successful oral acyclovir desensitization Ann Allergy 1993 70386—8

43. Reiff-Eldndge RA, Heffner CR, Ephross SA, Tennis PS, White AD, Andrews EB Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries a pharmaceutical company commitment Am J Obstet Gynecol 2000, 182 159—63

44. Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD, Jr Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes Obstet Gynecol 1996,87 69-73

45. Brocklehurst P, Kinghom G, Camey 0, et al A randomised placebo controlled trial of suppressive acylovir in late pregnancy in women with recurrent genital herpes infection Br J Obstet Gynaecol 1998 105 275-80

46. Thorpe ЕМ, Stamm WE, Hook EW, et al Chlamydial cervic itis and urethntis single dose treatment compared with doxycycline for seven days in community-based practices Gemtounn Med 1996 72 93-7

47. Stamm WE, Hicks CB, Martin DH, et al Azithromycin for empirical treatment of the nongonococcal urethntis syndrome in men a randomized double-blind study JAMA 1995 274 545-9

48. Adair CD, GunterM, Stovall TG, McElvoy G, VeilleJC. ErmentJM Chlamydia in pregnancy a randomized trial of azithromycin and enthromycin Obstet Gynecol 1998 91 165-8

49. Wehbeh НА, Ruggeino RM, Shakem S, Lopez G, All Y Single dose azithromycin for chlamydia in pregnant women J Reprod Med 1998 43 509-14

50. MoranJS, Levine WC Drugs of choice for the treatment of uncompli­cated gonococcal infections Clin Infect Dis 1995,20(Suppl 1),S47—S65

51. Haimovici R, Rous'selTJ Treatment of gonococcal conjunctivitis with single-dose intramuscular ceftnaxone Am J Ophthalmol 1989 107 511

52. Hauth JC, Goldenberg RL. Andrews WW, DuBard MB, Copper RL Reduced incidence ofpreterm delivery with metromdazole and eryth-romycin in women with bacterial vaginosis N Engi J Med 1995 333 1732-6

53. Morales WJ Schorr S, Albntton J Effect of metromdazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis a placebo-controlled, double-blind study 'Am J Obstet Gynecol 1994 171 345-9

54. McDonald ИМ, O'LoughlinJA, Vigneswaran R, etal Impact of met­romdazole thei ару on preterm birth in women with bacterial vaginosis flosa (Gardnerella vagmalis) a randomised, placebo controlled trial BrJObslet Gynaecol 1997 104 1391-7

55. Jack&on P, Rid ley WJ, Pattison NS Single dose metromdazole prophylaxis in gynaecological surgery NZ Med J 1979 89 243-5

56. WillisAT Metromdazole in the prevention and treatment of Bacleroides infections in gynaecological patients Lancet 1974,2 1540-3

57. PerssonE, BergstromM, LarswnPG, etal Infections after hysterec-tomv и prospective nationw ide Swedish Study Acta Obstetnca et Gynecologiaca Scandinavica 1996 75 757-61

58. Larsson PG, Platz-Chnstenven JJ, Forsum U, Pahlson С Clue cells in predicting infections after abdominal hysterectomy Obstet Gynecol 1991,77 450-2

59. Newton ER Pnhoda TJ. Gibbs RS A clinical and microbiologic analysis of risk factors for puerperal endotnetntis Obstet Gynecol 1990 75 402-6

60. Soper DE, Bump RC, Hurt WG Bacterial vaginosis and Inc ho manias i¹, agimtiv are rifk factors fui cuff ceilulitis after abdominal h steiectomy Am] Obstet Gynecol /990,163 1016-21

61. Watts DH Krohn MA, Hillier SL, Eschenbach DA Bacterial vaginosis ач a risk factor for post-f ечагеап endometnti ? Obstet Gynecol 1990 75 52-8

62. Sihcr HM, SperiingRS Sf Glair PJ, Gibbs RS Evidence relating bacterial vaginow ю inti aammotic infection Am J Obstet Gynecol 1989 161 808-12

63. B/ornerem A, Aghajam E MaltauJM.MoiH Occurrence of bacterial vagino4is among abortion seekers Tidssknft for Den Norske Laegeforemng 1997, i 17 1282-4

64. Hamark В, Foreman L Postabortal endometntis in chlamydia-negative women-association with preoperative clinical signs of infection Gvnecol Obstet Invest 1991 31 102-5

65. Lars чоп PG, Bergman В fo! sum U, Platz-Chnstensen JJ, Pahlson С Mobiluncus and clue cells as predictors ofPID after first-trimester abortion Acta Obstetnca ei Gvnecologica Scandinavica 1989 68 217-20

66. Hillier SL, Marcus J, Krohn M, Kiviat N, Holmes KK, Eschenbach DA A case-control study of chonoammomc infection and histologic chorioamniomti4 in prematurity New Engi J Med 1998 319 972-8

67. Livengood СН, Ш, Super DE, Sheehan KL, et al Companson of once-daily and twice-daily dosing ofO 75% metromdazole gel in the treatment of bacterial vaginosis Sex Transm Dis 1999,26 137—42

68. Sobel J Peipert JF, McGregor JA, et al Efficacy of clindamycin vaginal ovule vs clindamycin vaginal cream in bacterial vaginosis Infect Dis Obfitet Gynecol 2002 (in press}

69. Moi H, Erkkola R, Jerve F, et al Should male consorts of women with bacterial vaginosiv be treated⁹ Gemtounn Med 1989 65 263—8

70. Colli E Landoni M, Parazzim F, et al Treatment of male partners and recurrence of bacterial vaginosis a randomised trial Gemtounn Med 1997 73 267-70

71. VejtorpM.BollcrupAC.VejtorpL, etal Bacterial vaginosis adouble-blind randomized trial of the effect of treatment of the sexual partner BrJ Obstet Gynaecol 1988 95 920-6

72. McGregor JA, French Jl, Jones W, et al Bacterial vaginosis is associ­ated with prematurity and vaginal fluid mucinase andsialidase results of a controlled trial of topical clindamycin cream Am J Obstet Gynecol 1994 170 1048-59

73. JoesoefMR, Hilher SL, Wihyosastro G, et al Intravagmal chndamycin treatment for bacterial vaginosis effects on preterm delivery and low birth weight Am J Obstet Gynecol 1995 173 1527-31

74. Vermeulen GM, Bruinse HW Prophylactic administration of chndamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk a randomised placebo-controlled double-blind ti lal Br J Obstet Gynaecol 1999 106 652-7

75. Caro-Paton T, Carvajal A Martin de Diego I Maitin-Anas LH, Alvarez Requejo A Is metromdazole teratogemc^/> A meta-analysis BrJClin Pharmacol 1997 44 179-82

76. Burtin P, Taddio A, Anburnu О Einarwn TR Koren G Safety of metromdazole in pregnancy a meta-analysis Am J Obstet Gynecol 1995,172 525-9

77. Piper JM, Mitchel Ef, Ray WA Prenatal use of metromdazole and birth defects no association Obstet Gynecol 1993,82 348-52

78. Carey JC, KlebanoffMA, Hauth JC et al Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis New Engi J Med 2000 342 534-40

79. Hay PE, Ugwumadii ANN, Jeffrey I, Manvonda JT Oral chndamycin prevent'! spontaneous pretei т birth and mid trimester miscarriage in pregnant women with bacterial vaginosis Int J STD AIDS 2001.12(Suppl2) 70-1

80. PearlmanMD, Yashaf C, Ernst S, Solomon W An incremental dosing protocol for women with severe vaginal tnchomoniasis and adverse reactions to metromdazole Am J Obstet Gynecol 1996, 174 934-6

81. KlebanoffMA, Caiev JC, Hauth JC et al Failure of metromdazole to prevent preterm delivery among pregnant women with asymptomatic Tnchomonas vagmalis infection New Engi J Med 2001 345 487-93

82. Walker CK, Kahn JG, Washington 4E, Peterson HB, Sweet RL Pelvic inflammatory disease meta-analysis of antimicrobial regimen efficacy J Infect Dis 1993,168 969-78

83. Matsuda S Clinical study of levofloxacin (LVFX) on the infectious diseases in the field of obstetrics and gynecology Chemotherapy 1992,40311-23

84. Martens MG, Gordon S, Yarborough DR Faro S Binder D Berkeley A Multicenter randomized trial of ofloxacin veisus cefoxitin and doxv-cycline in outpatient treatment of pelvic inflammatory disease South MedJ 1993,86 604-10

85. PeipertJF, Sweet RL, Kahn J, Reilly-Gauvin К Evaluation of ofloxacin in the treatment of laparoscopically documented acute pelvic inflammatory disease (salpingitis) Infect Dis Obstet Gynecol 1999,7 138-4

86. Walker CK, Workowski KA, Washington AE Soper D, Sweet RL Anaerobes in pelvic inflammatory disease implications for the Centers for Disease Control and Preventions guidelines for treatment of sexually transmitted diseases dm Infect Dis I999,28(Suppl 1) S29-S36

87. Witte EH, Peters AA, Smit IB van der Linden MC, Mouton RP, van der Meer JW, van Erp EJ A comparison of pefloxacin/metronidazole and doxycycline/metromdazole in the treatment of laparoscopically confirmed acute pelvic inflammatory disease Eur J Obstet Gynecol ReprodBiol 1993,50 153-8

88. Ridgway GL, Bevan C, Siddle N Azithromycm with or without met­romdazole compared with cefoxitin, doxycycline and metromdazole in the treatment of laparoscopy confirmed acute pelvic inflammatory disease [Abstract] In Proceedings of the llth International Meeting of the International Society for STD Reseaich, New Orleans Fort Lee, New Jersey International Society for STD Research, 1995-

89. Cohen CR, Sinei S, Reilly M, et al Effect of human immunodefi­ciency virus type I infection upon acute salpingitis a laparoscopic study J Infect Dis 1998.178 1352-8

90. Bukesi EA, Cohen CR, Stevens CE et al Effects of human immuno­deficiency virus 1 infection on microbial origins of pelvic inflamma­tory disease and on efficacy of ambulatory oral therapy Am J Obstet Gynecol 1999 18 1374-81

91. Irwin KL, Moorman AC, 0 Sullivan MJ et al Influence of human immunodeficiency virus infection on pelvic inflammatory disease Obstet Gynecol 2000.95 525-34

92. Kamb ML Cervical cancer screening of women attending sexually transmitted diseases clinics Clin Infect Dis I995,20(Suppl 1) S98-S103

93. American Cancer Society Guidelines for the cancer related checkup Atlanta, Georgia American Cancer Society, 1998

94. American College of Obstetricians and Gynecologists Routine cancer screening committee opinion 185 Washington, DC American College of Obstetricians and Gynecologists, 1997

95. National Cancer Institute Workshop The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses JAMA 1989 262 931-4

96. JayN, Moscich AB Human papillomavirus infections in women with HIV disease prevalence, risk, and management [Review] AIDS Reader 2000,10659-68

97. Kurman RJ Henson DE Herbst AL, Noller KL, Schiffman MH, National Cancer Institute Workshop Interim guidelines for manage­ment of abnormal cervical cytology JAMA 1994,271 1866-9

98. MacKellar DA Valleroy LA Secura GM, et al Two decades after vac- cine license hepatitis В immunization and infection among young men who have sex with men Am J Public Health 2001,91 965-71

99. CDC Immunization of adolescents recommendations of the Advi­sory Committee on Immunization Practices, the American Academy of Pediatrics the American Academy of Family Physicians and the American Medical Association MMWR 1996 45 1-5

100. Mast ЕЕ, Williams IT, Alter MJ, Margolis HS Hepatitis В vaccina­tion of adolescent and adult high-risk groups in the United States Vaccine 1998,16(Suppl) S27-S29

101. Alter MJ, Kruszon-Moran D, Hainan 0V, et al The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engi J Med 1999,341 556-62

102. CDC Recommendations for prevention and control of hepatitis C virus (HCV) infection and HC\'-related chronic disease MMWR 1998,47 (No RR-19) 1-39

103. Diegstag JL Sexual and perinatal transmission of hepatitis C Hepatology 1997 26(Suppl 1) S66-S70

104. Alter MJ Epidemiology of hepatitis C Hepatology 1999 26 (Suppi 1) S25-S65

105. Thomas DL, Zemlman JM Alter MJ, et al Sexual transmission of hepatitis C virus among patients attending Baltimore sexually trans­mitted disease clinics an analysis of 309 sex partnerships J Infect Dis 1995 171 768-75

106. HisadaM, O'Bnen TR, RosenbergPS, GoederlJJ Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia the Multicenter Hemo-phiha Cohort Study J Infect Dis 2000 181 1475-8

107. BambergerJD, Waldo CR, Gerberding JL, Katz MH Postexposure prophylaxis foi human immunodeficiency virus (HIV) infection following sexual assault Am J Med 1999 106 323-6

108. CDC Public Health Service guidelines for the management of health care worker exposures to HIV and recommendations for post-exposure prophylaxis MMWR 1998,47'(No RR-7) 1-33

109. American Academy of Pediatrics Sexually transmitted disease in adolescents and children In Pickenng LK, ed 2000 Red book report of the Committee on Infectious Diseases 25dl ed Elk Grove Village, IL American Academy of Pediatrics, 2000 138-47

110. American Academy of Pediatrics Committee on Child Abuse and Neglect Guidelines for the evaluation of sexual abuse of children subject review Pediatrics 1999 103 186-91

111. Adams JA, Harper K, Krudson S A proposed system for the classifications of anogemtal findings in children with suspected child abuse Adolesc Pediatr Gynecol 1992 5 73-5

112. Shapiro RA, Schubert CJ, Siegel R Neissena gonorrhoeae infections in girls younger than 12 у ears of age evaluated for vagmitis Pediatrics 1999 104 (e72) l-ll

113. Lagerberg D Sexually transmitted diseases in children a serious con- sequence of sexual abuse and an indication of possible victimization of other children Acta Pediatrica 1998,87 1214-7

114. Dominguez KL Simonds RJ Postexposure prophylaxis In Zeichner SL, Read JS, eds Handbook of pediatnc HIV care Philadelphia Lippincott Williams & Wilkins, 1999 294-318.

Содержание